IR@PKUHSC  > 北京大学临床肿瘤学院  > 胃肠肿瘤中心
学科主题临床医学
Phase II study of nimotuzumab combination with paclitaxel and cisplatin as the first-line treatment in patients with local advanced or metastatic esophageal squamous cell cancer (ESCC): An interim analysis
Zhang, Xiaodong; Lu, Ming; Gong, Jifang; Gao, Jing; Wang, Xicheng; Zhang, Xiaotian; Li, Jie; Li, Yan; Li, Jian; Zhou, Jun; Lu, Zhihao; Shen, Lin
刊名JOURNAL OF CLINICAL ONCOLOGY
2012-05-20
suppl.S期:15
收录类别SCI ; ISTP
文章类型Meeting Abstract
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
语种英语
WOS记录号WOS:000318009804468
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/66514
专题北京大学临床肿瘤学院_胃肠肿瘤中心
作者单位1.Beijing Canc Hosp & Inst, Beijing, Peoples R China
2.Peking Univ, Canc Hosp, Beijing 100871, Peoples R China
3.Peking Univ, Sch Oncol, Dept Gastrointestinal Oncol, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Zhang, Xiaodong,Lu, Ming,Gong, Jifang,et al. Phase II study of nimotuzumab combination with paclitaxel and cisplatin as the first-line treatment in patients with local advanced or metastatic esophageal squamous cell cancer (ESCC): An interim analysis[J]. JOURNAL OF CLINICAL ONCOLOGY,2012,suppl.S(15).
APA Zhang, Xiaodong.,Lu, Ming.,Gong, Jifang.,Gao, Jing.,Wang, Xicheng.,...&Shen, Lin.(2012).Phase II study of nimotuzumab combination with paclitaxel and cisplatin as the first-line treatment in patients with local advanced or metastatic esophageal squamous cell cancer (ESCC): An interim analysis.JOURNAL OF CLINICAL ONCOLOGY,suppl.S(15).
MLA Zhang, Xiaodong,et al."Phase II study of nimotuzumab combination with paclitaxel and cisplatin as the first-line treatment in patients with local advanced or metastatic esophageal squamous cell cancer (ESCC): An interim analysis".JOURNAL OF CLINICAL ONCOLOGY suppl.S.15(2012).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhang, Xiaodong]的文章
[Lu, Ming]的文章
[Gong, Jifang]的文章
百度学术
百度学术中相似的文章
[Zhang, Xiaodong]的文章
[Lu, Ming]的文章
[Gong, Jifang]的文章
必应学术
必应学术中相似的文章
[Zhang, Xiaodong]的文章
[Lu, Ming]的文章
[Gong, Jifang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。